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Abstract
BACKGROUND—P-selectin (SELP) and its ligand, P-selectin glycoprotein ligand 1 (SELPLG),
play key roles in both the inflammatory response and the atherosclerotic process. Previous studies
have shown genetic variation in the SELP gene [selectin P (granule membrane protein 140kDa,
antigen CD62)] to be associated with plasma SELP concentrations; however, the major biological
function of SELP (and SELPLG) is at the cell surface. We therefore investigated the association of
SELP polymorphisms with platelet SELP measures and polymorphisms in the SELPLG gene (selectin
P ligand) with lymphocyte, granulocyte, and monocyte SELPLG measures among 1870 participants
in the Atherosclerosis Risk in Communities (ARIC) Carotid MRI study.
METHODS—Whole-blood flow cytometry was used to analyze leukocyte and platelet markers in
the ARIC Carotid MRI study. The allele frequencies for the SELP and SELPLG polymorphisms of
whites and African Americans were markedly different; therefore, all analyses were race specific.
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RESULTS—SELP T715P was significantly associated with lower values for platelet SELP
measures in whites (P = 0.0001), whereas SELP N562D was significantly associated with higher
values for SELP measures in African Americans (P = 0.02). SELPLG M62I was significantly
associated with lower granulocyte and monocyte SEL-PLG measures in African Americans (P =
0.003 and P = 0.0002, respectively) and with lower lymphocyte SELPLG measures in whites (P =
0.01).
CONCLUSIONS—Specific SELP and SELPLG polymorphisms were associated with cell surface
measures of SELP and SELPLG in both whites and African Americans in the ARIC Carotid MRI
study. To our knowledge, this study is the first to examine the association of SELP and SELPLG
genetic variation with measures of cell surface SELP and SELPLG.
The pathogenesis of atherosclerosis is known to contain an important inflammatory component
involving the recruitment and adhesion of circulating leukocytes to the vascular endothelium
(1,2). P-selectin (SELP),6 a member of the selectin family of adhesion molecules, initiates
leukocyte rolling and mediates interactions of leukocytes with the endothelium, platelets with
the endothelium, and leukocytes with platelets (3–5). Leukocyte–endothelium and leukocyte–
platelet interactions require the presence of a counterligand on the leukocyte surface, P-selectin
glycoprotein ligand 1 (SELPLG) (6–8). Multiple studies have provided evidence supporting a
key role for SELP and SELPLG in atherosclerotic lesion formation, thrombosis, and arterial
wall changes (1,5,9–14).
Previous studies have shown variation in the SELP7 gene [selectin P (granule membrane
protein 140kDa, antigen CD62)] to be associated with the concentration of soluble SELP in
the plasma (15–18). However, the studies that have examined the association of SELP and
SELPLG concentrations with cardiovascular disease and those that have evaluated associations
of SELP and SELPLG (selectin P ligand) genetic variation with cardiovascular disease have
produced inconsistent results (8,19–26). The major biological function of SELP and SELPLG
is at the cell surface, where these cell adhesion molecules mediate the interaction of leukocytes,
platelets, and the endothelium (3–8). Although the concentration of soluble SELP has been
used as an indicator of platelet activation, measures of soluble SELP are affected by multiple
mechanisms, including active cleavage from the platelet surface, simple shedding from the
platelet surface, and direct secretion from the cell in the form of an alternatively spliced
SELP mRNA lacking the sequence encoding the protein’s transmembrane domain (5,27,28).
One can avoid the caveat of not having a clearly identifiable source of SELP by measuring it
on the cell surface with flow cytometry (5). To our knowledge, no study to date has examined
the relationship of SELP and SELPLG genetic variation to measures of SELP and SELPLG on
the cell surface. We investigated the association of 4 SELP polymorphisms with measures of
platelet SELP and the association of 2 SELPLG polymorphisms with lymphocyte, granulocyte,
and monocyte SELPLG measures among 1870 participants in the Atherosclerosis Risk in
Communities (ARIC) Carotid MRI study.
Materials and Methods
STUDY DESIGN AND STUDY PARTICIPANTS
The ARIC Carotid MRI study was conducted from 2004–2005 and included 2066 participants.
The participants were selected from the ARIC study cohort according to the results of the last
ultrasound examinations of the carotid artery (visits 3 and 4, 1993–1998). The participants
included those with high values for carotid artery wall thickness and a random sample of
6Nonstandard abbreviations: SELP, P-selectin; SELPLG, P-selectin glycoprotein ligand 1; ARIC, Atherosclerosis Risk in Communities;
CHD, coronary heart disease.
7Human genes: SELP, selectin P (granule membrane protein 140kDa, antigen CD62); SELPLG, selectin P ligand.
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participants with carotid arteries of typical thickness; equivalent numbers of participants were
selected from the 4 ARIC field centers. The ARIC study is a prospective investigation of
atherosclerosis and its clinical sequelae in 15 792 African American and white men and women
who were 45–64 years of age at the time of recruitment (1987–1989). Participants underwent
a baseline evaluation and had up to 3 follow-up visits through 1998. Detailed descriptions of
the ARIC study design and methods have been published elsewhere (29). The study was
approved by local institutional review boards. For the current analyses, participants were
excluded if they prohibited use of their DNA for research purposes or had missing information
for all measurement variables; approximately 1870 ARIC Carotid MRI participants were
ultimately available for analysis.
EXAMINATION AND LABORATORY MEASURES
All measures used in the described analyses were from the 2004–2005 MRI examination.
Seated blood pressure was measured 3 times with a random-zero sphygmomanometer, and the
mean of the last 2 measurements was used. Hypertension was defined as a systolic blood
pressure ≥140 mmHg, a diastolic blood pressure ≥90 mmHg, or current use of antihypertensive
medications. Diabetes was defined by a fasting glucose concentration ≥7.0 mmol/L (126 mg/
dL), a nonfasting glucose concentration ≥11.1 mmol/L (200 mg/dL), and/or a history of or
treatment for diabetes. Cigarette-smoking status was analyzed by comparing current smokers
to individuals who had formerly or never smoked. Body mass index (in kilograms per meter
squared) was calculated from height and weight measurements. Details of flow cytometry
measurements are provided elsewhere (30). In brief, flow cytometric analysis was performed
on a Coulter Epics XL instrument (Beckman Coulter). Strict internal quality-assurance
procedures were applied. The proportion of cells expressing the antigen of interest and the
relative level of antigen expression were assessed by measuring the median fluorescence
intensity. Data were extracted from the acquired flow cytometric list mode data files and
transferred into Microsoft Office Excel files.
GENOTYPE DETERMINATION
We selected the following SELP and SELPLG polymorphisms on the basis of their being
missense mutations or having previously been reported to be associated with coronary heart
disease (CHD) and/or stroke: SELP S290N (rs6131), SELP N562D (rs6127), SELP V599L
(rs6133), SELP T715P (rs6136), SELPLG 5′UTR (rs8179131), and SELPLG M62I
(rs2228315). Genotyping was carried out with SNPlex or TaqMan assays (Applied
Biosystems). Sequences for the primers and probes are available from the authors upon request.
The ARIC study has a rigorous blind duplicate program. The percent agreement for blind
duplicate data for these polymorphisms was 96.3% for SELP S290N, 94.8% for SELP N562D,
96.3% for SELP V599L, 97.8% for SELP T715P, 99.7% for SELPLG 5′UTR, and 97.3% for
SELPLG M62I.
STATISTICAL ANALYSIS
All analyses were based on methods appropriate for a stratified random sample. In particular,
all analyses were weighted by the inverse of the sampling fractions in the 8 sampling strata (4
field centers × 2 intima–media thickness groups). In brief, the ARIC Carotid MRI study
reexamined a subset of the original ARIC cohort. The participants were selected as described
above. The sampling fractions were based on those persons actually screened for participation.
SAS software (version 9.1, SAS Institute) was used for analysis of descriptive statistics (PROC
SURVEYMEANS, PROC SURVEYFREQ), and SUDAAN (RTI International) was used for
linear and logistic regression. Correction factors for finite populations were not applied. Tests
of differences between groups in weighted means or proportions were from weighted linear or
logistic regression models that accounted for the sampling. SUDAAN REGRESS was used
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for continuous variables to calculate adjusted means and proportions by subgroup of interest,
and LOGISTIC was used for dichotomous variables.
SUDAAN CROSSTAB was used to calculate genotype frequencies as weighted frequencies.
Allele frequencies were calculated from genotype frequencies; e.g., the frequency of allele A
was calculated as P(AA) + P(AB)/2, where P(AA) and P(AB) are the weighted frequencies
of genotypes AA and AB, respectively. The test for the Hardy–Weinberg equilibrium used the
weighted genotype frequencies and their covariance matrix, with the δ method applied to obtain
the test statistic. Variant alleles were identified as the low-frequency allele in white participants,
and homozygous nonvariant genotypes were designated as the referent group in the statistical
analyses.
Results
All SELP and SELPLG genotype distributions were in accordance with Hardy–Weinberg
equilibrium expectations. Whites and African Americans had markedly different allele
frequencies for each of the polymorphisms studied; consequently, we analyzed the racial
groups separately. When alleles were observed to be rare, heterozygous and homozygous
genotypes carrying the rare allele were combined for further genotype–phenotype analyses.
The SELPLG 5′UTR polymorphism was not polymorphic in the white participants; therefore,
results for this polymorphism are presented for African Americans only.
Table 1 presents SELP and SELPLG flow cytometry data by racial group, along with the results
for basic risk factors. White and African American ARIC participants differed significantly
with respect to all of the basic risk factors investigated except smoking status. Compared with
the white participants, the African American participants were younger, had a higher body
mass index, and had a higher proportion of diabetic and hypertensive individuals. African
Americans also had significantly higher values for all flow cytometry measures of SELP and
SELPLG than white participants (Table 1).
Table 2 presents SELP data for flow cytometry measures according to SELP genotype and
racial group. In whites only, SELP 715TP and 715PP genotypes were associated with
significantly lower values for platelet SELP measures compared with the 715TT genotype. In
African Americans only, the SELP 562ND and 562DD genotypes were associated with
significantly higher values for platelet SELP measures, compared with the 562NN genotype.
Table 3 presents SELPLG data for flow cytometry measures according to SELPLG genotype
and racial group. In whites, the SELPLG 62MI and 62II genotypes were associated with
significantly lower values for lymphocyte SELPLG measures compared with the 62MM
genotype. In African Americans, both the SELPLG 62MI and 62II genotypes (compared with
62MM) and the SELPLG 5′UTR GA and AA genotypes (compared with 5′UTR GG) were
associated with lower values for the lymphocyte, granulocyte, and monocyte SELPLG
measures.
Noting that we had previously found the SELPLG M62I polymorphism to be associated with
the risk of both incident CHD and incident ischemic stroke in African American participants
in the ARIC study (31), we further investigated whether the data for the SELP and SELPLG
flow cytometry measures were associated with disease status in the African American
participants of the ARIC Carotid MRI study. All values for SELP and SELPLG flow cytometry
measures were higher in the ischemic stroke case group than in the controls, but these findings
were not statistically significant (data not shown); however, the number of cases identified in
the ARIC Carotid MRI study was small (African American CHD cases, 24; stroke cases, 23).
We therefore do not have sufficient power to detect a difference in disease status with regard
to the flow cytometry measures.
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The major biological function of SELP and SELPLG is at the cell surface, where they mediate
the interaction of leukocytes, platelets, and the endothelium (3–8). Because multiple
mechanisms can produce changes in the values for soluble SELP, one can avoid the caveat of
not having a clearly identifiable source of SELP by measuring SELP, as well as SELPLG, on
the cell surface via flow cytometry (5). The current investigation of the ARIC Carotid MRI
study used flow cytometry to obtain values for cell surface measures of SELP and SELPLG.
We found SELPLG M62I to be associated with decreased values for lymphocyte SELPLG
measures in both whites and African Americans, as well as decreased values for granulocyte
and monocyte SELPLG in African Americans only. In a previous study, we found SELPLG
M62I to be associated with a decreased risk for both incident CHD and incident ischemic stroke
in African American participants in the ARIC study (31).
The SELPLG M62I polymorphism is positioned adjacent to the SELP-binding domain.
Although the functional consequence of the M62I polymorphism is unknown, the proximity
of this variant to the binding domain suggests that it has an effect on SELP binding (8,32). The
implication of SELP and SELPLG in the generation of procoagulant microparticles has
revealed novel roles for SELP and SELPLG in thrombosis and has led to the use of SELP
inhibitors as a therapeutic target for vascular and thrombotic diseases (5,33–36). SELPLG
could be considered as an alternative target for intervention. Variation in the SELPLG gene
that alters SELP/SELPLG binding capacity represents an important target in reducing the effect
of SELPLG molecules present on the cell surface, which may lead to fewer leukocyte–
endothelium and leukocyte–platelet complexes and a potential reduction in the risk of stroke.
The antibody used in the flow cytometry assay (KPL1) maps to a tyrosine-sulfation motif
positioned between amino acid residues 5 and 11 of SELPLG (37). Therefore, it is unlikely
that the SELPLG M62I polymorphism we have investigated has an impact on the affinity of
the KPL1 antibody used in the flow cytometry assay.
Although the number of cases within the ARIC Carotid MRI study was not adequate to
investigate the association of SELP and SELPLG flow cytometry measures with incident
ischemic stroke, all values for SELP and SELPLG flow cytometry measures were higher in
the stroke case group than in the controls. In a previous study, we had determined SELPLG
genetic variation to be associated with a decreased risk of incident ischemic stroke in the ARIC
cohort (31). Considering our previous findings along with the results of the current study (that
SELPLG genetic variation is associated with decreased values for cell surface measures of
SELPLG in the ARIC Carotid MRI study), we propose that this combined evidence strongly
supports the hypothesis that measures of cell surface SELPLG are related to the risk of incident
ischemic stroke. Of course, further studies are warranted to replicate the current findings, to
determine the causal relationship between SELPLG cell surface measures and the risk of
disease, and to determine the functional consequence of the SELPLG M62I polymorphism.
Furthermore, we must also consider that although the SELPLG M62I polymorphism was
associated with measures of SELPLG on the lymphocyte cell surface in both whites and African
Americans, the association with disease was statistically significant only for African
Americans. Therefore, our results cannot discern whether the SELPLG M62I polymorphism
itself has a direct causative effect; it may be in linkage disequilibrium with the true functional
variant(s). Given that linkage-disequilibrium patterns of whites and African Americans are
different, if we are not investigating the true functional variant, we may have detected an
association with a “marker” polymorphism in one race and not the other.
Results from the current study demonstrate that the SELPLG M62I polymorphism is associated
with significantly lower values for SELPLG granulocyte and monocyte measures in African
Americans; this polymorphism also exhibits a strong trend of association with lower values
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for SELPLG lymphocyte measures in both whites and African Americans. A possible
mechanism by which the SELPLG M62I polymorphism might affect disease risk is by altering
the affinity of SELP to bind to SELPLG, thereby attenuating the recruitment and adhesion of
leukocytes and platelets to the endothelium wall and/or reducing leukocyte–platelet aggregates.
To our knowledge, no study to date has examined the association of SELP and SELPLG genetic
variation with SELP and SELPLG cell surface measures. Further studies are warranted to
replicate the current findings in other large US populations of whites and African Americans
and to determine the functional consequence of the SELPLG M62I polymorphism. These
results, when considered together with prior research on SELP and SELPLG function and if
replicated in future studies, provide preliminary evidence that could lead to new targets for
therapeutic intervention.
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Table 1
ARIC Carotid MRI basic risk factors and flow cytometry measures by race.a
Whites (n = 1411) African Americans (n = 459) P
Basic risk factors
 Age, years 70.6 (5.5) 69.2 (5.5) <0.0001
 BMI,b kg/m2 28.5 (5.1) 31.4 (6.0) <.0001
 Male sex, % 45.8 35.3 0.0009
 Smoker, % 7.2 9.9 0.1
 Diabetic, % 21.1 36.9 <.0001
 Hypertensive, % 61.3 78.0 <.0001
Flow cytometry measures
 Platelet SELP, % 27.6 (13.1) 30.9 (15.7) 0.0008
 Platelet SELP, MFI 21.5 (5.1) 22.8 (6.2) 0.0008
 Lymphocyte SELPLG, MFI 51.8 (10.0) 59.6 (10.8) <.0001
 Granulocyte SELPLG, MFI 76.7 (14.1) 88.4 (14.3) <.0001
 Monocyte SELPLG, MFI 111.6 (15.5) 114.6 (14.1) 0.001
a
Data are presented as the mean (SD) or as a percentage, as indicated.
b
BMI, body mass index; MFI, median fluorescence intensity.
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